RxDoctor Payments Data

Lisa Zimmerman, DO

Family Medicine · Reading, PANPI 1114289865

Payments from drug & device makers

$453in general payments, 2019–2025

Across 32 payments — averaging $14.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$83
  • GSK$64
  • Novartis$64
  • Novo Nordisk$58
  • Pfizer$41
  • Lilly USA, LLC$35
  • plus $108 from 7 others

What the payments were for

  • Food & beverage$453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$453 in reported general payments places this provider in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$219,126
Medicare patients
608
Services billed
2,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban178$175,972
JardianceEmpagliflozin134$140,301
XareltoRivaroxaban48$55,512
TrulicityDulaglutide54$54,095
MounjaroTirzepatide30$40,021
OzempicSemaglutide34$39,700
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$21,328
InvokanaCanagliflozin13$20,418
JanuviaSitagliptin Phosphate18$19,414
Breo ElliptaFluticasone/Vilanterol25$14,634
FarxigaDapagliflozin Propanediol13$14,219
Tresiba Flextouch U-100Insulin Degludec11$11,664
MyrbetriqMirabegron11$9,735
Atorvastatin Calcium895$9,671
SynthroidLevothyroxine Sodium128$8,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$175,972178 claims
Boehringer IngelheimJardiance$12$140,301134 claims
Lilly USA, LLCTrulicity, Mounjaro$35$94,11684 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$64$39,88562 claims
Novo NordiskOzempic$58$39,70034 claims
AstraZenecaFarxiga$83$14,21913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Reading

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →